Higher IOP may be marker for CVD

Article

Higher IOP may be a predictable marker of cardiovascular disease (CVD) in some individuals, according to a study from South Korea.

Higher IOP may be a predictable marker of cardiovascular disease (CVD) in some individuals, according to a study from South Korea published in the British Journal of Ophthalmology. The researchers found that higher IOP is associated with the presence of coronary artery calcium (CAC) in asymptomatic patients, regardless of the presence of usual cardiovascular risk factors.

The researchers’ cross-sectional study included 10,732 men and women without diagnoses of CVD or glaucoma. They measured CAC using cardiac computed tomography and IOP using a non-contact tonometer and automatic air puff control.

The researchers detected CAC in 13.7% in men and 4.3% of women. They found that increasing levels of right IOP were significantly associated with an increased prevalence of CAC. They adjusted for multiple factors - age, sex, tobacco use, alcohol use, physical activity, body mass index, educational level, centre, family history of CVD, use of dyslipidemia medication, diabetes, hypertension, total cholesterol level, high-density lipoprotein cholesterol and triglycerides - and found that the odds ratios for CAC score >0, comparing 2–4 quartiles of the right IOP with the lowest quartiles, were 1.32, 1.20 and 1.28, respectively. The associations were the same among the clinically relevant subgroups.

Recent Videos
David Yorston, FRCS, FRCOphth, discusses his EURETINA keynote lecture
Hoda Shamsnajafabadi, MSc, PhD, presents at the 2024 EURETINA meeting
Timothy L Jackson PhD, MB ChB, FRCOphth, speaks about a combination therapy for VEGF-A/C/D inhibition with sozinibercept and ranibizumab
Carl Awh, MD, FASRS, speaks about the American Society of Retina Specialists (ASRS) at EURETINA
Stefano Mercuri, MD, first author of the winning eposter “Genotype-phenotype correlations in a cohort of genetically determined Retinitis Pigmentosa (RP) Italian patients with Rho gene mutations”
Bahram Bodaghi, MD, PHD, FEBO at the 2024 EURETINA meeting
Enrico Borrelli, MD, FEBO, speaks at EURETINA
Aleksandra Rachitskaya, MD, FASRS, speaks about the Vit-Buckle Society at the 2024 EURETINA Congress.
© 2024 MJH Life Sciences

All rights reserved.